Drug Search Results
More Filters [+]

HN-0001

Alternative Names: HN-0001, HN 0001, HN0001
Latest Update: 2024-08-27
Latest Update Note: Clinical Trial Update

Product Description

mRNA/LNP COVID-19 Booster Vaccine. (Sourced from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=387220)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: HelixNano Australia Pty Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HN-0001

Countries in Clinic: Australia

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACTRN12624000719538

P1

Not yet recruiting

COVID-19

2025-01-25

ACTRN12624000715572

P1

Recruiting

COVID-19

2024-09-06

Recent News Events

Date

Type

Title